Compare American Electric Power Company Inc (AEP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs Incyte Corporation — how do they compare? American Electric Power Company Inc trades at $123.95 (market cap $67.28B), while Incyte Corporation trades at $120.5 (market cap $24.54B). The key difference: American Electric Power Company Inc is far larger — about 2.7× Incyte Corporation's market cap, and American Electric Power Company Inc pays a 3.07% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AEP | INCY | |
|---|---|---|
Market Cap | $67.28B | $24.54B |
Sector | Utilities | Health |
52-Week High | $138.69 | $129.93 |
52-Week Low | $106.44 | $81.61 |
Enterprise Value | $120.17B | $20.04B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $122.84, down 2.3% on the day, with a bearish technical signal. Recent Q2 2026 earnings missed estimates at $1.36 per share versus $1.48 expected, though revenue grew 7% year-over-year. The company raised full-year 2026 operating EPS guidance to $6.25–$6.55, supported by 69 GW of contracted load and a $78 billion capital plan. Analyst consensus remains strongly bullish with a $140.89 price target and no sell ratings.
The outlook is positive due to robust demand from data centers and infrastructure growth, but risks include high capital expenditures and interest expenses. Valuation metrics like a P/E of 21.42 are elevated, requiring sustained earnings growth to justify. The stock offers a stable dividend, with the next payment of $0.95 ex-dividend on August 10, 2026.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
